Autonomix Touts RF Ablation Tech’s Ability to Reduce Opioid Use

 100% of the responder group went to zero opioid use at 4-6 weeks post-procedure

Up to 75% of late-stage pancreatic cancer patients are prescribed opioids and data suggests 20% are at risk for abuse and misuse1

Data from the initial “lead-in” cohort show responders experienced a reduction in pain assessed by VAS from 8.0 pre-procedure to 1.33 at 4-6 weeks post-procedure

https://www.globenewswire.com/news-release/2024/10/28/2970023/0/en/Positive-Preliminary-Results-Demonstrate-Autonomix-s-Proprietary-RF-Ablation-Technology-s-Ability-to-Reduce-Opioid-Use-in-Ongoing-Human-Clinical-Trial.html